Forte Biosciences (FBRX) Misses Q3 EPS by 2c

Go back to Forte Biosciences (FBRX) Misses Q3 EPS by 2c

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

November 14, 2022 4:01 PM EST

 -FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications-

-Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors-

-Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents-

DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc.... More